[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.145.124. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,046
Citations 0
Research Letter
December 18, 2018

Prostate Cancer–Specific Mortality Across Gleason Scores in Black vs Nonblack Men

Author Affiliations
  • 1Harvard Radiation Oncology Program, Boston, Massachusetts
  • 2Department of Medicine, University of California, San Francisco
  • 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco
JAMA. 2018;320(23):2479-2481. doi:10.1001/jama.2018.11716

The Gleason score is the best independent predictor of prostate cancer outcomes.1 The principle distinction between Gleason 6 disease vs Gleason 7 to 10 disease is that Gleason 6 disease does not necessarily need definitive treatment.2 Nevertheless, the implications of Gleason score are less clear in black men because of disparate prostate cancer outcomes, particularly for Gleason 6 disease, in which risk assessment and management of disease in black men is controversial.2,3 We investigated prostate cancer–specific mortality by Gleason score and race.

×